Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes

References

• Centers for Disease Control and Prevention. National diabetes statistics report, 2017. Atlanta, GA: Center for Disease Control and Prevention, US Dept of Health and Human Services; 2017.
   Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS data brief, no 288. Hyattsville, MD: National Center for Health Statistics. 2017.
   Google Scholar
• Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:4037–4043.
   PubMed Web of Science ®Google Scholar
• Pani LN, Nathan DM, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care. 2008;31:386–390.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374–1383.
   PubMed Web of Science ®Google Scholar
• UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism. 1990;39:905–912.
   PubMed Web of Science ®Google Scholar
• Pastors JG, Warshaw H, Daly A, et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002;25:608–613.
   PubMed Web of Science ®Google Scholar
• Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–2514.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation. 2014;129:S102–38.
   PubMed Web of Science ®Google Scholar
• Franz MJ, Boucher JL, Rutten-Ramos S, et al. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115:1447–1463.
   PubMed Web of Science ®Google Scholar
• Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2017;391:541–551.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018 March 22. published online. DOI:10.2337/dci18-0007
   Web of Science ®Google Scholar
• Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin. 2007;23:2157–2169.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care. 2018;41(Suppl 1):S73–S85.
   PubMed Web of Science ®Google Scholar
• Corbett AH, Golembiewski JA, Gonzales JP, et al. Eds. Lexicomp drug information handbook. 26th Ed. Sacramento, CA: Wolters Kluwer; 2017–2018.
   Google Scholar
• Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21:323–329.
   PubMed Web of Science ®Google Scholar
• Bray GA, Edelstein SL, Crandall JP, et al. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012;35:731–737.
   PubMed Web of Science ®Google Scholar
• Van Dieren S, Czernichow S, Chalmers J, et al. Weight changes and their predictors amongst 11,140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab. 2012;14:464–469.
   PubMed Web of Science ®Google Scholar
• Domecq JP, Prutsky G, Leppin A, et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:363–370.
   PubMed Web of Science ®Google Scholar
• Glucophage (metformin hydrochloride) tablets [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2017.
   Google Scholar
• Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open. 2014;2:E162–75.
   PubMedGoogle Scholar
• Gagnon J, Sheppard E, Anini Y. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes Metab. 2013;15:276–279.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550–554.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.
   PubMed Web of Science ®Google Scholar
• Kostev K, Rex J, Rockel T, et al. Effects of selected antidiabetics on weight loss: a retrospective database analysis. Prim Care Diabetes. 2015;9:74–77.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401–2411.
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–2637.
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410–1418.
   PubMed Web of Science ®Google Scholar
• Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13:594–603.
   PubMed Web of Science ®Google Scholar
• Wang Z, Xu D, Huang L, et al. Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes. Diabetes Res Clin Pract. 2017;130:77–85.
   PubMed Web of Science ®Google Scholar
• Lind M. Incretin therapy and its effect on body weight in patients with diabetes. Prim Care Diabetes. 2012;6:187–191.
   PubMed Web of Science ®Google Scholar
• Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [Corrected] Vasc Health Risk Manag. 2012;8:463–472.
   PubMedGoogle Scholar
• Lau DC, Teoh H. Impact of current and emerging glucose-lowering drugs on body weight in type 2 diabetes. Can J Diabetes. 2015;39(Suppl 5):S148–54.
   PubMedGoogle Scholar
• Amaryl (glimepiride) tablets [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2013.
   Google Scholar
• Actos (Pioglitazone) tablets [prescribing information]. Deerfield, IL 60015: Takeda Pharmaceuticals America, Inc.; 2017.
   Google Scholar
• Derosa G, Maffioli P. Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011;91:265–270.
   PubMed Web of Science ®Google Scholar
• Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003;115(Suppl8A):42S–8S.
   PubMedGoogle Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–2791.
   PubMed Web of Science ®Google Scholar
• Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 2005;54:24–32.
   PubMed Web of Science ®Google Scholar
• Burcelin R, Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Obes Rev. 2017;18:86–98.
   PubMed Web of Science ®Google Scholar
• Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524–536.
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251–260.
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258–266.
   PubMed Web of Science ®Google Scholar
• Van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:784–793.
   PubMed Web of Science ®Google Scholar
• Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34:1174–1186.
   PubMed Web of Science ®Google Scholar
• Lean M, Le Roux C, Fujioka K, et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise program [Abstract #611]. Endocr Pract. 2015;21:118–119.
   Google Scholar
• Morano S, Romagnoli E, Filardi T, et al. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetol. 2015;52:727–732.
   PubMed Web of Science ®Google Scholar
• Lockie SH, Heppner KM, Chaudhary N, et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012;61:2753–2762.
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270.
   PubMed Web of Science ®Google Scholar
• Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016; published online. 2016 Nov 11. DOI:10.1371/journal.pone.0166125
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Chen YH, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018; published online. 2018 Jan 20. DOI:10.1161/JAHA.117.007165.
   Web of Science ®Google Scholar
• Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016; published online. 2016 Feb 24. DOI:10.1136/bmjopen-2015-009417
   PubMed Web of Science ®Google Scholar
• Cai X, Yang W, Gao X, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity (Silver Spring). 2018;26:70–80.
   PubMed Web of Science ®Google Scholar
• Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721–728.
   PubMed Web of Science ®Google Scholar
• Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–1735.
   PubMed Web of Science ®Google Scholar
• Rajeev SP, Sprung VS, Roberts C, et al. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol. BMJ Open. 2017; published online. 2017 Jan 27. DOI:10.1136/bmjopen-2016-013539.
   PubMedGoogle Scholar
• Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism. 2014;63:1228–1237.
   PubMed Web of Science ®Google Scholar
• Cinti F, Moffa S, Impronta F, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017;11:2905–2919.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154–2161.
   Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–1195.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950.
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149.
   PubMed Web of Science ®Google Scholar
• Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087–1095.
   PubMed Web of Science ®Google Scholar
• Miki T, Liss B, Minami K, et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci. 2001;4:507–512.
   PubMed Web of Science ®Google Scholar
• Lee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018;41:104–111.
   PubMed Web of Science ®Google Scholar
• Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004–1016.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:2099.
   PubMed Web of Science ®Google Scholar
• Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017;40:821–831.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–870.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460–1470.
   PubMed Web of Science ®Google Scholar
• Cariou B, Charbonnel B. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2015;24:1647–1656.
   PubMed Web of Science ®Google Scholar
• Fouqueray P, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013;36:565–568.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Paquot N, Lefebvre PJ. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert Opin Investig Drugs. 2017;26:1373–1389.
   PubMed Web of Science ®Google Scholar
• Saxenda (liraglutide) injection [prescribing information]. Bagsvaerd, Denmark: Novo Nordisk; 2016.
   Google Scholar
• O’Neill PM, Birkenfeld AL, McGowan B, et al. A randomized, phase II, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes [abstract OR12–5]. Endocrine Society Annual Meeting; March 2018; Chicago, IL
   Google Scholar
• Chukir T, Shukla AP, Saunders KH, et al. Pharmacotherapy for obesity in individuals with type 2 diabetes. Expert Opin Pharmacother. 2018;19:223–231.
   PubMed Web of Science ®Google Scholar